Clinical Trials Browser

Phase 2 × OTHER × LY-2157299 × Clear all

NCT02452008 2025-12-19

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04605562 2021-09-05

Umbrella Biomarker-Guided Therapy in NPC

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma